Hypoxic versus normoxic external-beam irradiation of cervical carcinoma combined with californium-252 neutron brachytherapy: Comparative treatment results of a 5-year randomized study

Strahlentherapie und Onkologie

Volumn 181, Issue 5, 2005, Pages 273-284

  Tačev, Tačo ^a   Vacek, Antonín ^b   Ptáčková, Blanka ^a   Strnad, Vratislav ^c  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b INSTITUTE OF BIOPHYSICS   (Czech Republic)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Californium 252; Cervical carcinoma; Hypoxyradiotherapy; Side effects and complications; Treatment results

Indexed keywords

CALIFORNIUM 252;

BEAM THERAPY; BRACHYTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; CYSTOVAGINAL FISTULA; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; OXYGENATION; PROCTITIS; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RECTOUTERINE POUCH; RECTUM ULCER; REVIEW; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; BRACHYTHERAPY; CALIFORNIUM; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEUTRONS; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS;

EID: 20044390213     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-005-1303-0     Document Type: Review

References (52)

1. Chvorostenko MI, Krugovov BA, Kosse BA, et al. Vlijanie kratkovremennoj gazavoj gipoxii (7,8-8,2%) na organism zdorovogo cheloveka i onkologicheskich bolnych. Med Radiol 1986;6:14-8.
2. Fawler JF. Chemical modifiers of radiosensitivity - theory and reality: a review. Int J Radiat Oncol Biol Phys 1985;11:665-76.
3. Feola JM, Nava A, Maruyama Y. Biological effects of Cf-252 neutrons at low dose rate. Int J Radiat Biol 1982;41:33-46.
4. Fields PR. Transplutonium elements in thermonuclear test debris. Phys Rev 1956;102:180.
5. Gragg RL, Huphrey PM, Thames HD Jr, et al. The response of Chinese hamster ovary cells to fast neutron radiotherapy beams: III. Variation in relative biological effectiveness with position in the cell cycle. Radiat Res 1978;76:283-9.
6. Gray LH, Conger AD, Ebert M, et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;25:538-48.
7. Haie C, Pejovic MH, Gerbaulet A, et al. Is prophylactic para-aortic irradiation worthwhile in treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC Radiotherapy Group. Radiother Oncol 1988;11:101-12.
8. Hall EJ. A comparison of radium and californium-252 using cultured mammalian cells. Radiology 1972;102:173-9.
9. Hall EJ, Roizin-Towle LA, Colvett RD. RBE and OER determination for radium and californium-252. Radiology 1974;110:699-701.
10. Henk JM. Late results of a trial of hyperbaric oxygen and radiotherapy in head and neck cancer: a rationale for hypoxic cell sensitisers. Int J Radiat Oncol Biol Phys 1986;12:1339-41.
11. Hille A, Weiss E, Hess CF. Therapeutic outcome and prognostic factors in the radiotherapy of recurrences of cervical carcinoma following surgery. Strahlenther Onkol 2003;179:742-7.
12. 3H mouse mammary tumours. Br J Radiol 1972;45:250-6.
13. Kosse VA. Combined treatment of gastric cancer using hypoxic radiotherapy. Vopr Onkol 1990;36:1349-53.
14. 252Cf sources for neutron brachytherapy. Appl Radiat Isot 1997;48:1567-70.
15. Maruyama Y, Beach JL, Feola J. Scheduling of hypoxic tumor therapy using neutron brachytherapy. Radiology 1980;137:775-8.
16. Maruyama Y, Feola J, Beach JL. A tumor/normal tissue advantage for low dose rate neutron brachytherapy. Int J Radiat Oncol Biol Phys 1983;9:1715-21.
17. Maruyama Y, Kryscio R, Van Nagel J R, et al. Clinical trial of Cf-252 neutron brachytherapy for advanced cervical cancer. Int J Radiat Oncol Biol Phys 1983;11:1475-82.
18. Maruyama Y, Yoneda J, Krolikiewicz H, et al. A clinical trial for advanced cervico-vaginal pelvis carcinomas using californium-252 fast neutron therapy: report of early responses. Int J Radiat Oncol Biol Phys 1980;6:1629-37.
19. Mayer A, Nemeskeri C, Petnehazi C, et al. Primary radiotherapy of stage IIA/B-IIIB cervical carcinoma. A comparison of continuous versus sequential regimens. Strahlenther Onkol 2004;180:209-15.
20. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-43.
21. Neumeister K, Révész L. Advances in hypoxyradiotherapy. Int J Radiat Oncol Biol Phys 1987;13:424-31.
22. Révész L, Palcic B. Radiation dose dependence of the sensitization by oxygen and oxygen minic sensitizers. Acta Radiol Oncol 1985;24:209-17.
23. 252Cf brachytherapy sources. Med Phys 2000;27:2816-20.
24. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-53.
25. Rotman M, Pajak TF, Choi K, et al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stage IIb and bulky Ib and IIa cervical carcinomas. Ten-year treatment results of RTOG 79-20. JAMA 1995;274:387-93.
26. Silberstein AB, Aron BS, Alexander LL. Para-aortic lymph node irradiation in cervical carcinoma. Radiology 1970;95:181-4.
27. Steel GG, Peacock JH. Why are some human tumours more radiosensitive than others? Radiother Oncol 1989;15:63-72.
28. Strnad V, Grebmeier J, Riepl M, et al. Hypoxia-radiotherapy: the changes in selected physiological parameters of healthy tissue during the breathing of a hypoxic gas mixture. Strahlenther Onkol 1994;170:571-80.
29. Strnad V, Kamprad F, Jahns J, et al. Regression of Yoshida sarcoma during normoxia and hypoxia after fractionated irradiation. Strahlenther Onkol 1997;173:141-5.
30. Strnad V, Sauer R, Tačev T. Hypoxieradiotherapie. Die radioprotektive Wirkung der akuten Hypoxie in der Strahlentherapie von Tumoren im abdominellen Bereich. Strahlenther Onkol 1994;170:700-3.
31. Tačev T, Grigorov G, Papírek T, et al. Remote afterloading for neutron brachytherapy using californium-252. Strahlenther Onkol 2003;179:113-7.
32. Tačev T, Kryštof V, Rašovska O, et al. A study of intracavitary application of californium-252 in cancer of the uterine cervix and the use of hypoxytherapy in external radiation. Final report of Research Project No P12-561-817-06/07 SPTR in 1990.
33. Tačev T, Prokeš B, Strnad V, et al. Effect of small doses of 252-Cf on the tumour regression in cervix uteri during combined radiotherapy. Strahlenther Onkol 1989;165:837-43.
34. 252Cf) versus conventional gamma radiation in the brachytherapy of advanced cervical carcinoma. Long-term treatment results of a randomized study. Strahlenther Onkol 2003;179:377-84.
35. Tačev T, Ptáčková B, Strnad V, et al. Importance of californium-252 for a better radio-curability of carcinoma of the cervix uteri: long-time treatment results presented. Klin Onkol 2001;14:59-64.
36. Tačev T, Ptáčková B, Vacek A, et al. The relationship of Cf-252 and Ra-226 radiation doses to the reoxygenation and regression of cervix uteri tumors. Part II: Preliminary results in advanced cervical carcinoma. In: Wierzbicki JG, ed. Californium-252 isotope for 21st century radiotherapy. NATO ASI Series 3, High technology, vol 29. Dordrecht-Boston-London: Kluwer Academic, 1997:77-82.
37. Tačev T, Ptáčková B, Vacek A, et al. Californium-252 and hypoxyradiotherapy in treatment of advanced carcinoma of the cervix uteri. In: Wierzbicki J, ed. Californium-252 isotope for 21st century radiotherapy. NATO ASI Series 3, High technology, vol 29. Dordrecht-Boston- London: Kluwer Academic, 1997:83-97.
38. Tačev T, Skříčka T, Žaloudík J, et al. Preoperative hypoxyradiotherapy of colorectal carcinoma. Strahlenther Onkol 2002;178:676-81.
39. Tačev T, Strnad V, Vacek A. Radiotherapy of cervix uteri carcinoma with 252-Cf and hypoxyradiotherapy in the course of external irradiation. Radiosensitization Newsletter 1991;10:10-2.
40. Tačev T, Strnad V, Vacek A, et al. Radiotherapy of cervix uteri carcinoma with Cf-252 implant and external hypoxyradiotherapy. Nucl Sci Appl 1991;4:201-12.
41. Tačev T, Vacek A, Prokeš B, et al. The relationship of Cf-252 and Ra-226 radiation doses to the reoxygenation and regression of cervix uteri tumors. Part I: Clinical experimental study. In: Wierzbicki JG, ed. Californium-252 isotope for 21st century radiotherapy. NATO ASI Series 3, High technology, vol 29. Dordrecht-Boston-London: Kluwer Academic, 1997:57-75.
42. 2. Klin Onkol 1990;3:140-5.
43. Tačev T, Vacek A, Strnad V, et al. Hypoxyradiotherapy of uterine cervix cancer to decrease acute side effects and treatment complications. Strahlenther Onkol 1990;166:710-3.
44. Thomson SG, Street K, Chiroso A, et al. The new element californium (atomic number 98). Phys Rev 1950;80:790-6.
45. Vacek A, Rotkovská D, Bartoníčková A, et al. Differences in radioprotective effects of hypoxia in normal tissues and in experimental tumors. Int J Radiat Biol 1986;49:858.
46. Vacek A, Tačev T, Hofer M. Modulation of radioprotective effects of respiratory hypoxia by changing the duration of hypoxia before irradiation and combining hypoxia and administration of hemopoiesis-stimulating agents. Strahlenther Onkol 2001;177:474-81.
47. Warthon JT, Jones HW, Day TG, et al. Preirradiation coeliotomy and extended field irradiation for invasive carcinoma of the cervix. Obstet Gynecol 1977;49:333-8.
48. Weitmann HD, Gustorff B, Vaupel P, et al. Oxygenation status of cervical carcinomas before and during spinal anesthesia for application of brachytherapy. Strahlenther Onkol 2003;179:633-40.
49. Wierzbicki JG, ed. Californium-252 isotope for 21st century radiotherapy. NATO ASI Series 3, High technology, vol 29. Dordrecht-Boston-London: Kluwer Academic, 1997.
50. Yaes RJ. Tumour heterogeneity, tumor size and radioresistance. Int J Radiat Oncol Biol Phys 1989;7:993-1005.
51. Yarmonenko SP. Radiobiology of humans and animals. Moscow: Mir, 1988.
52. Yarmonenko SP, Vajnson AA, Bereznova LI, et al. The selective protection of normal tissues by irradiation of tumor-bearing mice in hypoxic hypoxia. Radiat Res 1976;67:447-58.